Modulating bacterial MAM polypeptides in pathogenic disease
View Patent ↗The disclosure relates to methods and compositions for preventing or inhibiting pathogenic bacterial infections in a subject caused by pathogenic bacteria expressing a multivalent adhesion molecule (MAM) polypeptide by administering to a subject a composition comprising a MAM polypeptide or a non-pathogenic bacterium expressing a MAM polypeptide, or a combination thereof.
1. A method of preventing or inhibiting a pathogenic bacterial infection in a subject caused by a pathogenic bacterium expressing a multivalent adhesion molecule (MAM) polypeptide, comprising administering to said subject a composition comprising a non-pathogenic bacterium expressing a MAM polypeptide comprising at least 6 mce repeat regions.
2. The method of claim 1 , wherein said pathogenic bacterium is Gram-negative.
3. The method of claim 2 , wherein said pathogenic bacterium is selected from the group consisting of Vibrio parahaemolyticus, Vibrio cholerae, Yersinia pseutotuberculosis , and enteropathogenic Escherichia coli.
4. The method of claim 1 , wherein said non-pathogenic bacterium expresses a native MAM polypeptide.
5. The method of claim 1 , wherein said non-pathogenic bacterium expresses a heterologous MAM polypeptide.
6. The method of claim 5 , wherein said non-pathogenic bacterium comprises a gene encoding a MAM polypeptide in an extrachromosomal self-replicating vector.
7. The method of claim 5 , wherein said non-pathogenic bacterium comprises a gene encoding a MAM polypeptide integrated into a chromosome of said non-pathogenic bacterium.
8. The method of claim 1 , wherein said composition further comprises a probiotic.
9. The method of claim 8 , wherein said composition is administered orally.
10. The method of claim 8 , wherein said composition is selected from the group consisting of milk, yogurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae, pet food, a tablet, a liquid bacterial suspension, dried oral supplement and wet oral supplement.
11. The method of claim 1 , wherein said composition is administered topically.
12. The method of claim 11 , wherein said subject has suffered a burn injury.
13. The method of claim 11 , wherein said composition is formulated as a cream, a gel, a salve, an ointment or a powder.
14. The method of claim 11 , wherein said composition is comprised in or disposed on a wound dressing.
15. The method of claim 1 , wherein said composition is comprises in or disposed on a surgical mesh or implantable device.
16. A method of preventing or inhibiting a pathogenic bacterial infection in a subject caused by a pathogenic bacterium expressing a multivalent adhesion molecule (MAM) polypeptide, comprising administering to said subject a composition comprising a MAM peptide or protein comprising at least 6 mce repeat regions coupled to a carrier.
17. The method of claim 16 , wherein said pathogenic bacterium is Gram-negative.
18. The method of claim 17 , wherein said pathogenic bacterium is selected from the group consisting of Vibrio parahaemolyticus, Vibrio cholerae, Yersinia pseutotuberculosis , and enteropathogenic Escherichia coli.
19. The method of claim 16 , wherein said carrier is a particle or bead.
20. A method for identifying or quantifying phosphatidic acid on a membrane comprising contacting a membrane with a peptide or polypeptide comprising a multivalent adhesion molecule (MAM) mce repeat region.
21. The method of claim 20 , wherein said membrane is part of an intact cell.
22. The method of claim 1 , wherein the number of mce repeats is 6.
23. The method of claim 1 , wherein the number of mce repeats is 7.
24. The method of claim 16 , wherein the number of mce repeats is 6.
25. The method of claim 16 , wherein the number of mce repeats is 7.
26. The method of claim 16 , wherein said carrier is a liposome, a nanoparticle, a nanoshell, a nanocluster or a quantum dot.